Cost Effectiveness Analysis of Eribulin Mesylate (Halaven®) as a Treatment for Metastatic Breast Cancer in Mexico.

Sorry, there's nothing here.

Cite this paper

@article{Jones2015CostEA, title={Cost Effectiveness Analysis of Eribulin Mesylate (Halaven®) as a Treatment for Metastatic Breast Cancer in Mexico.}, author={Tito Jones and Germain Tremblay and Unnati Majethia and Eileen Saunders and J G Gay Molina and R Gonzalez Balboa and Y Huesca}, journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research}, year={2015}, volume={18 7}, pages={A822} }